Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas
For patients on these medications, high-dose oral supplementation or injections are clinically necessary to bypass the digestive blockade
Other warning signs include persistent vomiting that prevents adequate fluid intake, signs of dehydration, or symptoms of gallbladder problems such as pain in the upper right abdomen
Discussion In this mechanistic analysis of the SUMMIT trial, we found that, compared with placebo, treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist tirzepatide reduced BP and estimates of circulatory volume expansion in patients with obesity-related HFpEF
Lancet Diabetes Endocrinol 6(4): 275-286
US$ 29.86
US$ 21.58
US$ 27.49
US$ 24.38
US$ 27.88
